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Abstract
Chikungunya virus is a mosquito-borne virus that has been responsible for over 2 million human 
infections during the past decade. This virus, which previously had a geographical range primarily 
restricted to sub-Saharan Africa, the Indian subcontinent and South East Asia, has recently moved 
to subtropical latitudes as well as the western hemisphere. This expansion into novel habitats 
brings unique risks associated with further spread of the virus and the disease it causes.
Chikungunya virus (CHIKV) is one of 31 distinct viruses in the family Togaviridae and the 
genus Alphavirus. Like most of the alphaviruses, CHIKV is a mosquito-borne, zoonotic 
virus that is maintained in a cycle between forest dwelling Aedes spp. mosquitoes (e.g. Ae. 
furcifer, Ae. africanus) and non-human primates (Jupp & McIntosh, 1988). Genetically, the 
virus has a ssRNA genome and characterized strains of the virus have been divided into 
three distinct genotypes that historically were based upon geography (Fig. 1). With the 
spread of the virus over the past decade, the genotypes have expanded significantly beyond 
their historical geographical origins with the East, Central and South African (ECSA) 
genotype spread throughout South East Asia and the Asian genotype in Oceania and the 
Americas. While there is up to approximately 15 % nucleotide divergence between the 
genotypes, the viruses cannot be distinguished antigenically from each other (Powers et al., 
2000).
Prior to 2006, CHIKV was a little known agent outside its enzootic distribution and the few 
sites of epidemics. While there have been large documented outbreaks in Thailand in 1962–
1964 and in India in 1963–1964 and 1974 (Halstead et al., 1969; Mavalankar et al., 2008), 
no large scale epidemic activity was reported for over 30 years when in 2004–2005 
outbreaks occurred in Kenya and Comoros resulting in over 250 000 infections (Sergon et 
al., 2007, 2008). After the outbreak in Comoros subsided in the fall of 2005, there was an 
unexpected resurgence of activity in the French overseas territory of La Réunion. With the 
onset of the rainy season in December, a tremendous increase in cases occurred in early 
2006 when approximately 40 000 cases per week were reported. This increase in cases was 
associated with a single amino acid change in the E1 gene (alanine to valine at position 226), 
which was found to increase the ability of the virus to be transmitted by Ae. albopictus 
mosquitoes, the predominant mosquito vector on La Réunion (Vazeille et al., 2007). Because 
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the primary historical epidemic vector, Ae. aegypti, was not prevalent on this island, the 
epidemic may have been halted in 2006 if this mutation had not emerged. From the epidemic 
in La Réunion, which resulted in an estimated 266 000 cases, numerous viraemic individuals 
were identified in multiple countries after travellers to La Réunion became infected on the 
island and then returned to their home countries while still infectious. In particular, several 
European countries including France, Italy and Spain (where the vector mosquito Ae. 
albopictus was established), documented imported cases (Soumahoro et al., 2010). The virus 
was also exported from La Réunion to India where an estimated 1.3 million infections 
occurred during the first year of the outbreak alone and the ECSA genotype was detected for 
the first time outside Africa (Mavalankar et al., 2008). Given this significant number of 
infections, not unexpectedly, the virus continued to move to new regions with transmission 
reported in multiple countries of South East Asia. In 2007, the virus was introduced into 
Italy via a viraemic traveller from India, this time resulting in autochthonous transmission in 
the Ravenna region of Italy. The number of cases was small (<300) and the outbreak limited 
by the onset of cooler weather combined with a rapid local mosquito eradication 
programme, but the localized transmission of CHIKV in a subtropical region led to 
significant concerns for other regions not previously exposed to CHIKV but with the 
presence of the epidemic vectors (Rezza et al., 2007). The epidemic continued to spread 
further in 2009 and 2010 with a large outbreak of almost 50 000 people in southern Thailand 
(Rianthavorn et al., 2010) as well as reported local transmission for the first time in China 
(Wu et al., 2012). Activity continued in 2011, but interestingly not only as an extension of 
the ongoing outbreak but with at least two independent outbreaks as well. The first was a 
small cluster of four cases in New Caledonia. While the number of cases found was limited, 
this detection was significant as the infecting agent was determined to be of the Asian 
genotype, clearly indicating the independent emergence of the virus from a distinct cycle 
(Dupont-Rouzeyrol et al., 2012). Another independent emergence was detected that same 
year in Republic of Congo where the ECSA genotype was found, but the lineage was 
distinct from that found in the Indian Ocean islands (Kelvin, 2011). Both Asian and ECSA 
genotypes were detected in 2012 with further outbreaks of CHIKV in the Philippines, 
Cambodia, Papua New Guinea, Malaysia, Bhutan and in the Middle East (Yemen) for the 
first time (Zayed et al., 2012). The number of cases continued to increase in 2013 with a 
record number of local cases in Singapore (992), a record number of imported cases in 
Australia (127), and new emergence of the virus (Asian genotype) in the Federated States of 
Micronesia (Yap) affecting over 900 individuals (MOH, 2014; ProMED-mail, 2014). The 
sequences of isolates from Yap were virtually identical to those from the Philippines and 
China in 2012, demonstrating the movement of the Asian genotype from East Asia to the 
western Pacific (Lanciotti & Valadere, 2014). The movement of this lineage further 
continued in late 2013.
Even with the exceptional number of cases as early as 2005 (~250 000 cases in Kenya and 
Comoros), broader awareness of CHIKV did not occur until the epidemic moved to the 
island of La Réunion. As the La Réunion outbreak progressed, great awareness of the virus 
resulted from the intense media attention generated by reports of infected travellers moving 
the virus from outbreak regions to new habitats. This was of particular note and concern 
when the virus was not only identified in areas of coastal Italy but also found being 
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transmitted autochthonously. Up to this point, the predominant epidemic vector Ae. aegypti 
was not present in Italy. Due to this unexpected event, public health officers throughout 
South East Asia, India and Pacific Ocean islands, and now Europe were increasing their 
surveillance efforts. Additionally, as infected travellers were identified in the French West 
Indies, French Guiana, USA, Canada and Brazil, surveillance and preparedness efforts were 
increasing in the western hemisphere as well. The increased reporting and visibility of the 
ongoing CHIKV epidemic at least partially contributed to the identification of the virus in 
additional countries where the virus had never previously been, and CHIKV laboratory 
testing was therefore likely not a priority. One such example was the detection in New 
Caledonia when four cases of CHIKV infection were confirmed in 2011. Similarly, the 
identification of CHIKV in Yemen in 2012, which occurred during a dengue virus outbreak, 
may not have resulted had the local officials not been aware of the increased risk of CHIKV 
transmission. Increased awareness of the possibility of CHIKV transmission in subtropical 
areas and new ecological niches may have also contributed to the finding of local 
transmission in south-western France in 2011.
As early as 2007, concerns of transmission of CHIKV in Europe and the Americas were 
additionally heightened by the recognition of the unique risks associated with the presence 
of the virus in these ecologies where the virus had never before been transmitted. First, the 
lack of any previous exposure meant that entire populations were susceptible as no pre-
existing immunity was present. While other alphaviruses such as Sindbis virus, Mayaro 
virus and the equine encephalitis viruses existed in Europe and the Americas, they would 
have been unlikely to provide any cross-protection against CHIKV even if a substantial 
proportion of the population had antibodies to them. Second, both of the known epidemic 
vectors, Ae. aegypti and Ae. albopictus, were present in substantial geographical areas not 
previously affected. Ae. albopictus was known to be present in southern portions of Europe 
and the USA, while both mosquito vectors were broadly distributed throughout Central and 
South America and the Caribbean. Given the range of the mosquito vectors and the 
population of the naive areas, over 500 million people would be estimated to be at risk of 
infection in the Americas alone. Third, because CHIKV would not have been a pathogen 
considered in the differential diagnosis of febrile illness in previously unaffected regions, 
clinician awareness of the virus, the clinical presentation and diagnostic options would have 
been widely unknown. Additionally, clinical diagnosis would be challenging because the 
signs and symptoms of CHIKV infection are similar to those of malaria, dengue fever, 
leptospirosis and numerous other agents that are commonly found in many of the tropical 
areas of the Americas. In particular, CHIKV infection appears clinically to be extremely 
similar to dengue fever, with illness onset characterized by rapid onset of a high fever 
(>102°F) and severe joint pain that may be accompanied by other signs and symptoms such 
as generalized maculopapular rash. Like dengue fever, CHIKV infection may result in 
lymphopenia or thrombocytopenia, but these laboratory parameters are not sufficient for 
diagnosis (Staples et al., 2009) leaving clinicians unfamiliar with CHIKV unable to easily 
distinguish these similar illnesses. Fourth, before significant cases were identified in the new 
areas, diagnosis would be further confounded by the limited regional availability of CHIKV 
reagents or diagnostic kits as well as laboratory personnel trained in the implementation of 
specific CHIKV testing protocols. With the increased awareness of CHIKV emergence and 
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movement, more options are now becoming available but the distribution of these products is 
sometimes limited. Broader development and commercialization of reagents and kits, while 
relieving some of the burden on the public health system, brings an additional challenge as 
these products are often lacking in external validation leading to the possibility of inaccurate 
results. If diagnostic assays were to miss true positive samples, public health officials could 
be unaware of transmission foci until the extensive activity would preclude a timely 
response. All of these concerns associated with the potential introduction of the virus into 
new areas such as the western hemisphere were amplified by the ability of infected 
individuals to move rapidly anywhere within the world. The long duration of viraemia (up to 
1 week) exacerbates the likelihood that a viraemic traveller will still be infectious to local 
mosquitoes upon their return to previously unaffected areas. Of these significant risks 
recognized to be issues of concern before the virus reached new ecological habitats, two of 
these (the training of public health personnel and development of reagents) could both be 
overcome with training, communication and the dissemination of epidemiological 
information.
Given the ever increasing risk of CHIKV expansion, substantial preparedness activities were 
undertaken by public health agencies in the USA, Latin America and Europe. The Centers 
for Disease Control and Prevention (CDC) in collaboration with the Pan American Health 
Organization (PAHO) developed and published preparedness guidelines for the eventual 
arrival of CHIKV in the Americas and the Caribbean subregion (PAHO, 2011, 2012). These 
documents encompass a variety of topics of interest to public health officials including 
information on epidemiology, clinical presentation, case management, laboratory testing, 
mosquito surveillance and control, and risk and outbreak communications. Similar reference 
materials were developed by the European CDC (ECDC) for European Countries (ECDC, 
2014). While the first of these guidelines were published in 2011 for the Americas, 
surveillance and preparedness activities continued with the hope that the virus would not 
invade the Americas despite the lack of any barriers to introduction and the known risks 
specific to the area. However, in late 2013, local transmission of CHIKV did indeed occur 
with the reports in December of the first activity identified in the Caribbean island of St. 
Martin (Omarjee et al., 2014). Rapid identification and characterization of the virus 
indicated that the virus was of the Asian genotype and most closely related to strains from 
East Asia and Yap. By the end of 2013, the virus had been discovered in four Caribbean 
countries with approximately 300 suspected cases. Following the characteristic pattern of 
rapid spread of the virus, local transmission has been reported in 26 Caribbean countries, 
four countries in South America, three countries in Central America and one country in 
North America with an estimated 651 000 cases in just the first 9 months after the reported 
introduction to the Americas (Fig. 2) (Fischer et al., 2014; PAHO, 2014). In July of 2014, 
local transmission of CHIKV was detected for the first time in Florida, USA. To date, no 
localized transmission has been reported elsewhere in the USA but 44 states documented 
travel-associated cases as of 16 September 2014. Many of these states are not likely to be at 
risk of local transmission because the relevant vectors are not present. However, many 
southern and east coast states could be at risk of autochthonous transmission. Information 
regarding the vectors involved in the western hemisphere transmission has not yet been 
verified but both Ae. aegypti and Ae. albopictus in the Americas have been shown to be 
Powers Page 4
J Gen Virol. Author manuscript; available in PMC 2020 March 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
permissive for CHIKV. With the high attack rates of CHIKV and the highly suitable 
conditions for spread in the Americas (and other new habitats), continued spread of CHIKV 
is certainly expected. However, the efforts undertaken to prepare for the introduction of this 
pathogen have increased awareness of the need for continued monitoring for novel 
pathogens and emergence events of this nature in our global community.
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Fig. 1. 
Countries and territories where local transmission of chikungunya virus has been reported. 
Reported genotype distribution is noted by colour. (Figure courtesy of Nicole Lindsey, 
CDC.)
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Fig. 2. 
Countries and territories in the Americas where locally acquired cases of chikungunya virus 
have been reported from PAHO (as of 9 September 2014), figure from http://www.cdc.gov/
chikungunya/geo/americas.html.
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